ABSI vs RXRX
ABSI and RXRX side by side — valuation & fundamentals (public data).
Key statistics
| Metric | ABSIABSCI CORP | RXRXRECURSION PHARMACEUTICALS, INC. |
|---|---|---|
| Market cap | $1.38B | $1.70B |
| P/S | 487.6x | 22.7x |
| Revenue growth (YoY) | -38.2% | 26.9% |
| Earnings growth (YoY) | -11.7% | -39.1% |
| EBIT margin | -4297.0% | -867.9% |
| ROE | -46.8% | -70.5% |
| ROIC | -84.6% | -175.2% |
| 1y total return | +194.1% | -34.4% |
Figures from SEC filings · for reference only · not investment advice
Crecimiento de $10,000: ABSI frente a RXRX
| Métrica | ABSI | RXRX |
|---|---|---|
| Valor final | $3.7K | $885 |
| Retorno total | -62.9% | -91.2% |
| CAGR | -17.5% | -37.5% |
| Volatilidad | 97.7% | 92.7% |
| Sharpe | 0.24 | -0.12 |
| Sortino | 0.37 | -0.18 |
| Caída máxima | -96.2% | -92.1% |
Basado en 1294 días de negociación comunes, 2021-07-22 → 2026-09-16 · tasa libre de riesgo 4.11% (bono corto del Tesoro actual, mantenido constante)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
Related comparisons
Delayed data · Public sources · For reference only · Not investment advice (this page declares no winner)